- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02062931
Autologous Mesenchymal Stem Cells Transplantation In Women With Premature Ovarian Failure
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Contact
- Name: Sayed Bakry, PhD
- Phone Number: +201006609978
- Email: sayed.bakry@yahoo.com
Study Contact Backup
- Name: Yehia Wafa, MD
- Phone Number: +201223101547
- Email: yehiawafa@hotmail.com
Study Locations
-
-
-
Cairo, Egypt
- Recruiting
- Al-Azhar University hospitals and Al Azhar Regenerative Medicine International Center (ARMIC)
-
Contact:
- Yehia Wafa, MD
- Phone Number: +201223101547
- Email: yehiawafa@hotmail.com
-
Contact:
- Mahmoud Edessy, MD
- Phone Number: +201005646785
- Email: dredessy@gmail.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Post-menarche female less than 40 years old.
- Follicle-stimulating hormone (FSH) more than or equal to 20 IU/L.
- Female with normal karyotyping.
- Agree to sign the designed consent for the study.
Exclusion Criteria:
- Pregnancy and lactation.
- Autoimmune diseases.
- Breast cancer, ovarian cancer.
- Female with abnormal karyotyping (e.g. turner syndrome, fragile X syndrome….).
- Hypersensitivity to any Gonadotropin-releasing hormone (GnRH) analogs.
- Patients with secondary ovarian failure (e.g. hypothalamic causes)
- Those with major medical problems such as malignancy, hepatitis, etc.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Stem Cell Preparation and Injection
Stem Cell Preparation and Injection: Stem Cells 60 ml of bone marrow will aspirated and used for stem cells isolation. Then stem cells will cultured using autologous serum, characterized and prepared and suspended in platelets rich plasma (PRP) using GMP rules and finally injected into ovarian tissues and ligaments . Stem Cell Dose: 3-5 Million Autologous MSCs Injected into Ovarian tissue. |
Stem Cells 60 ml of bone marrow will aspirated using local anathesia and used for stem cells isolation. Then stem cells will cultured using autologous serum, characterized and prepared. Blood sample drawn from venous blood centrifuged and then platelets rich plasma (PRP) collected. The purified and collected stem cells suspended in platelets rich plasma (PRP) using GMP rules and finally injected into ovarian tissues and ligaments . Stem Cell Dose: 3-5 Million Autologous MSCs Injected into Ovarian tissue. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Improvement of Cases
Time Frame: 48 Weeks
|
Decrease in serum FSH level.
Elevation in serum estrogen level.
Elevation in serum AMH level.
|
48 Weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Improvement of Cases
Time Frame: 48 Weeks
|
Participants were followed up monthly(Every 4WKs) and Assessed by: Hormonal Assessment. Clinical Assessment. Ultra Sound Assessment. Disappearance of Menopausal Symptoms. Pregnancy rate within 1 year. Miscarriage rate within one year of injection. Long term follow-up for any adverse effect, assessed for one year from injection. |
48 Weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Mahmoud Edessy, MD, Al-Azhar University
- Study Director: Sayed Bakry, PhD, Al-Azhar University
- Study Chair: Hala Gabr, MD, Cairo University
- Study Chair: Medhat Kamel, MSc, Al-Azhar University
- Principal Investigator: Yehia Wafa, MD, Al-Azhar University
- Study Chair: Hasan Tarabay, MD, Al-Azhar University
- Study Chair: Youssef Abu Shady, MD, Al-Azhar University
- Study Chair: Hala Hosni, MD, Cairo University
- Study Chair: Wael Abu Elkhier, MD, Military Academy
- Study Chair: Hamza El Tahan, BSc, Al-Azhar University
Publications and helpful links
General Publications
- M. Edessy, Hala N. Hosni, Y. Wafa, S Bakry, Y.Shady and M.Kamel. Stem Cells Transplantation in Premature Ovarian Failure.World Journal of Medical Sciences 10 (1): 12-16, 2014
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- NCT223101547
- AzharU223101547 (Registry Identifier: AzharU223101547)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Premature Ovarian Failure
-
Forever Young d.o.o.Medigroup Health System, Jevremova hospital; Saint James Hospital Malta; Re-medika...UnknownMenopause | Menopause, Premature | Premature Ovarian Failure | Ovarian Failure, Premature | Ovarian Failure | Ovarian Insufficiency | Ovarian Insufficiency, Primary | Premature Ovarian Failure 2A | Premature Ovarian Failure 3 | Premature Ovarian Failure 4 | Premature Ovarian Failure 1 | Premature Ovarian Failure... and other conditionsMalta, North Macedonia, Serbia
-
Ascendance BiomedicalCompletedInfertility | Menopause | Menopause, Premature | Infertility, Female | Premature Ovarian Failure | Menopause Related Conditions | Perimenopausal Disorder | Infertility Unexplained | Menopause Premature Symptomatic | Menopause Premature Asymptomatic | Premature Ovarian Failure, Familial | Premature Ovarian Failure... and other conditionsUnited States
-
Shenzhen Beike Bio-Technology Co., Ltd.UnknownPremature Ovarian Failure,China
-
Assistance Publique - Hôpitaux de ParisNot yet recruitingPremature Ovarian Failure (POF)France
-
Instituto de Investigacion Sanitaria La FeUnknownPremature Ovarian Failure (POF)Spain
-
Assistance Publique - Hôpitaux de ParisCompletedFamilial Premature Ovarian FailureFrance
-
Genesis Athens ClinicNational and Kapodistrian University of AthensRecruitingMenopause, Premature | Menopausal Syndrome | Premature Ovarian Failure | Ovarian Failure, Premature | Menopause Related ConditionsGreece
-
UMC UtrechtUniversity Medical Center Groningen; Erasmus Medical Center; Catharina Ziekenhuis... and other collaboratorsUnknownPremature Ovarian Failure (POF) | Incipient Ovarian Failure | Poor Response After Ovarian Hyperstimulation | Early Menopause | Hypergonadotropic AmenorrheaNetherlands
-
Equipo Juana CrespoUnknownIVF | Premature Ovarian Failure | Ovarian FailureSpain
-
Acibadem UniversityCompletedPremature Ovarian Failure | Diminished Ovarian ReserveTurkey
Clinical Trials on Stem Cell Preparation and Injection
-
ShiCang YuNot yet recruitingLarge Area BurnsChina
-
Royan InstituteCompletedCerebral PalsyIran, Islamic Republic of
-
Royan InstituteCompletedCerebral PalsyIran, Islamic Republic of
-
Royan InstituteCompletedTibial FractureIran, Islamic Republic of
-
Northwestern UniversityTerminated
-
Royan InstituteCompletedHip OsteoarthritisIran, Islamic Republic of
-
Royan InstituteCompletedAmyotrophic Lateral SclerosisIran, Islamic Republic of
-
Great Ormond Street Hospital for Children NHS Foundation...CompletedDilated Cardiomyopathy
-
Ageless Regenerative InstituteInstituto de Medicina RegenerativaWithdrawn
-
Instituto de Investigación Sanitaria de la Fundación...CompletedPerianal FistulaSpain